The Bluetooth Special Interest Group (SIG) has named Asthmapolis the winner in the Product Category of the Bluetooth Breakthrough Awards. The awards recognize innovative products and apps that use Bluetooth wireless technology. Asthmapolis, which uses inhaler sensors and mobile apps to transmit and track data on patient use of inhalers, was one of five finalists for … [Read more...] about Asthmapolis wins Bluetooth Breakthrough Award
Business
Nexus6 gets more than $4 million in funding for Smartinhaler
Smartinhaler developer Nexus6 has raised NZ$1.6 million (US$1.34 million) from existing investors plus NZ$3 (US$2.5 million) from BioScience Managers, with additional funding expected to bring the total to NZ$5 million by the close of the round in March. The company says it will use the money to expand global sales and marketing of the Smartinhaler range of inhaler … [Read more...] about Nexus6 gets more than $4 million in funding for Smartinhaler
Chiesi looks to acquire Cornerstone Therapeutics
According to North Carolina-based Cornerstone Therapeutics, Chiesi Farmaceutici has offered to purchase shares of Cornerstone's common stock for between $6.40 and $6.70 per share, to take the company private. Chiesi already owns approximately 60% of the outstanding shares of Cornerstone's common stock. No decision has been made by Cornerstone's board of directors at … [Read more...] about Chiesi looks to acquire Cornerstone Therapeutics
Quintiles to go public again
CRO Quintiles says that it has filed a registration statement with the US. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of an undisclosed number of shares of common stock. The company says that it plans to use the proceeds to pay down debt and "for general corporate purposes." Quintiles previously went public in 1994, then went private … [Read more...] about Quintiles to go public again
Discovery Labs gets $30 million for development of respiratory distress syndrome therapies
Discovery Laboratories says that Deerfield Management Company will provide the company up to $30 million in the form of a secured loan facility. Discovery Labs will use the money for development and commercialization of its Surfaxin lucinactant for the prevention of respiratory distress syndrome (RDS) in infants and Aerosurf aerosolized surfactant for the treatment of … [Read more...] about Discovery Labs gets $30 million for development of respiratory distress syndrome therapies
MeadWestvaco expands preservative-free product manufacturing capacity
MeadWestvaco has announced a $7.5 million expansion of its pharmaceutical manufacturing Centre of Excellence in Hemer, Germany, an expansion the company attributes largely to growth in the preservative-free nasal product market. According to the company, the project includes additional capacity in clean room molding and assembly. MWV offers a number of spray pumps for … [Read more...] about MeadWestvaco expands preservative-free product manufacturing capacity
Mystic gets US patent for intranasal delivery technology
The US Patent and Trade Office (USPTO) has granted Mystic Pharmaceuticals US Patent No. 8,377,009, according to the company. The patent, titled “Intranasal Cartridge Devices,” covers technology for a delivery system based on Mystic's unit dose delivery platforms for liquid or dry intranasal formulations of drugs and biologics. Mystic President and CEO Timothy … [Read more...] about Mystic gets US patent for intranasal delivery technology
Pharmaxis gets financing for Bronchitol commercialization, negative recommendation from PADAC
According to Pharmaxis, the company has obtained up to $40 million from NovaQuest Pharma Opportunities Fund III for development, manufacturing, and commercialization of Bronchitol mannitol inhalation powder in the US and EU. At the same time, the company announced that Bronchitol had received a negative recommendation for the treatment of cystic fibrosis patients from … [Read more...] about Pharmaxis gets financing for Bronchitol commercialization, negative recommendation from PADAC
Allergan to acquire MAP Pharmaceuticals
Allergan will acquire Levadex inhaled dihydroergotamine developer MAP Pharmaceuticals for $25 per share. The two companies entered into an agreement to co-promote Levadex in January 2011, and MAP submitted an NDA for the product later that year. The FDA issued a complete response letter for Levadex in March 2012, and MAP resubmitted the NDA in October of that year. … [Read more...] about Allergan to acquire MAP Pharmaceuticals
Catalent to invest $20 million to expand inhalation capabilities
Catalent Pharma Solutions has announced that it will invest $20 million to enhance pMDI clinical and commercial supply capabilities, along with other enhancements, at its Inhalation Center of Excellence in Research Triangle Park (RTP), North Carolina. The company offers a range of development and manufacturing services for inhaled products and says that it also … [Read more...] about Catalent to invest $20 million to expand inhalation capabilities